Third time’s the charm for AZ hyperkalemia drug

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA approved Lokelma sodium zirconium cyclosilicate (ZS-9) to treat hyperkalemia in adults. AZ had received two CRLs for Lokelma following manufacturing concerns (see BioCentury Extra, March 17, 2017).

The European Commission approved the drug in the same indication in March...